Various cells retrovirally transduced with N-acetylgalactosoamine-6-sulfate sulfatase correct Morquio skin fibroblasts in vitro

G. Toietta, G. M. Severini, C. Traversari, S. Tomatsu, K. Sukegawa, S. Fukuda, N. Kondo, P. Tortora, C. Bordignon

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Gene therapy may provide a long-term approach to the treatment of mucopolysaccharidoses. As a first step toward the development of an effective gene therapy for mucopolysaccharidosis type IVA (Morquio syndrome), a recombinant retroviral vector, LGSN, derived from the LXSN vector, containing a full-length human wild-type N-acetylgalactosamine-6-sulfate sulfatase (GALNS) cDNA, was produced. Severe Morquio and normal donor fibroblasts were transduced by LGSN. GALNS activity in both Morquio and normal transduced cells was several fold higher than normal values. To measure the variability of GALNS expression among different transduced cells, we transduced normal and Morquio lymphoblastoid B cells and PBLs, human keratinocytes, murine myoblasts C2C12, and rabbit synoviocytes HIG-82 with LGSN. In all cases, an increase of GALNS activity after transduction was measured. In Morquio cells co-cultivated with enzyme-deficient transduced cells, we demonstrated enzyme uptake and persistence of GALNS activity above normal levels for up to 6 days. The uptake was mannose-6-phosphate dependent. Furthermore, we achieved clear evidence that LGSN transduction of Morquio fibroblasts led to correction of the metabolic defect. These results provide the first evidence that GALNS may be delivered either locally or systematically by various cells in an ex vivo gene therapy of MPS IVA.

Original languageEnglish
Pages (from-to)2007-2016
Number of pages10
JournalHuman Gene Therapy
Volume12
Issue number16
DOIs
Publication statusPublished - 2001

Fingerprint

N-acetylglucosamine-6-sulfatase
Mucopolysaccharidosis IV
Sulfates
Fibroblasts
Skin
Genetic Therapy
Mucopolysaccharidoses
Myoblasts
Enzymes
Keratinocytes
Reference Values
B-Lymphocytes
Complementary DNA
In Vitro Techniques
Rabbits

ASJC Scopus subject areas

  • Genetics

Cite this

Various cells retrovirally transduced with N-acetylgalactosoamine-6-sulfate sulfatase correct Morquio skin fibroblasts in vitro. / Toietta, G.; Severini, G. M.; Traversari, C.; Tomatsu, S.; Sukegawa, K.; Fukuda, S.; Kondo, N.; Tortora, P.; Bordignon, C.

In: Human Gene Therapy, Vol. 12, No. 16, 2001, p. 2007-2016.

Research output: Contribution to journalArticle

Toietta, G. ; Severini, G. M. ; Traversari, C. ; Tomatsu, S. ; Sukegawa, K. ; Fukuda, S. ; Kondo, N. ; Tortora, P. ; Bordignon, C. / Various cells retrovirally transduced with N-acetylgalactosoamine-6-sulfate sulfatase correct Morquio skin fibroblasts in vitro. In: Human Gene Therapy. 2001 ; Vol. 12, No. 16. pp. 2007-2016.
@article{8e424e1e42224267b28008dec01deca7,
title = "Various cells retrovirally transduced with N-acetylgalactosoamine-6-sulfate sulfatase correct Morquio skin fibroblasts in vitro",
abstract = "Gene therapy may provide a long-term approach to the treatment of mucopolysaccharidoses. As a first step toward the development of an effective gene therapy for mucopolysaccharidosis type IVA (Morquio syndrome), a recombinant retroviral vector, LGSN, derived from the LXSN vector, containing a full-length human wild-type N-acetylgalactosamine-6-sulfate sulfatase (GALNS) cDNA, was produced. Severe Morquio and normal donor fibroblasts were transduced by LGSN. GALNS activity in both Morquio and normal transduced cells was several fold higher than normal values. To measure the variability of GALNS expression among different transduced cells, we transduced normal and Morquio lymphoblastoid B cells and PBLs, human keratinocytes, murine myoblasts C2C12, and rabbit synoviocytes HIG-82 with LGSN. In all cases, an increase of GALNS activity after transduction was measured. In Morquio cells co-cultivated with enzyme-deficient transduced cells, we demonstrated enzyme uptake and persistence of GALNS activity above normal levels for up to 6 days. The uptake was mannose-6-phosphate dependent. Furthermore, we achieved clear evidence that LGSN transduction of Morquio fibroblasts led to correction of the metabolic defect. These results provide the first evidence that GALNS may be delivered either locally or systematically by various cells in an ex vivo gene therapy of MPS IVA.",
author = "G. Toietta and Severini, {G. M.} and C. Traversari and S. Tomatsu and K. Sukegawa and S. Fukuda and N. Kondo and P. Tortora and C. Bordignon",
year = "2001",
doi = "10.1089/104303401753204571",
language = "English",
volume = "12",
pages = "2007--2016",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "16",

}

TY - JOUR

T1 - Various cells retrovirally transduced with N-acetylgalactosoamine-6-sulfate sulfatase correct Morquio skin fibroblasts in vitro

AU - Toietta, G.

AU - Severini, G. M.

AU - Traversari, C.

AU - Tomatsu, S.

AU - Sukegawa, K.

AU - Fukuda, S.

AU - Kondo, N.

AU - Tortora, P.

AU - Bordignon, C.

PY - 2001

Y1 - 2001

N2 - Gene therapy may provide a long-term approach to the treatment of mucopolysaccharidoses. As a first step toward the development of an effective gene therapy for mucopolysaccharidosis type IVA (Morquio syndrome), a recombinant retroviral vector, LGSN, derived from the LXSN vector, containing a full-length human wild-type N-acetylgalactosamine-6-sulfate sulfatase (GALNS) cDNA, was produced. Severe Morquio and normal donor fibroblasts were transduced by LGSN. GALNS activity in both Morquio and normal transduced cells was several fold higher than normal values. To measure the variability of GALNS expression among different transduced cells, we transduced normal and Morquio lymphoblastoid B cells and PBLs, human keratinocytes, murine myoblasts C2C12, and rabbit synoviocytes HIG-82 with LGSN. In all cases, an increase of GALNS activity after transduction was measured. In Morquio cells co-cultivated with enzyme-deficient transduced cells, we demonstrated enzyme uptake and persistence of GALNS activity above normal levels for up to 6 days. The uptake was mannose-6-phosphate dependent. Furthermore, we achieved clear evidence that LGSN transduction of Morquio fibroblasts led to correction of the metabolic defect. These results provide the first evidence that GALNS may be delivered either locally or systematically by various cells in an ex vivo gene therapy of MPS IVA.

AB - Gene therapy may provide a long-term approach to the treatment of mucopolysaccharidoses. As a first step toward the development of an effective gene therapy for mucopolysaccharidosis type IVA (Morquio syndrome), a recombinant retroviral vector, LGSN, derived from the LXSN vector, containing a full-length human wild-type N-acetylgalactosamine-6-sulfate sulfatase (GALNS) cDNA, was produced. Severe Morquio and normal donor fibroblasts were transduced by LGSN. GALNS activity in both Morquio and normal transduced cells was several fold higher than normal values. To measure the variability of GALNS expression among different transduced cells, we transduced normal and Morquio lymphoblastoid B cells and PBLs, human keratinocytes, murine myoblasts C2C12, and rabbit synoviocytes HIG-82 with LGSN. In all cases, an increase of GALNS activity after transduction was measured. In Morquio cells co-cultivated with enzyme-deficient transduced cells, we demonstrated enzyme uptake and persistence of GALNS activity above normal levels for up to 6 days. The uptake was mannose-6-phosphate dependent. Furthermore, we achieved clear evidence that LGSN transduction of Morquio fibroblasts led to correction of the metabolic defect. These results provide the first evidence that GALNS may be delivered either locally or systematically by various cells in an ex vivo gene therapy of MPS IVA.

UR - http://www.scopus.com/inward/record.url?scp=0035195967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035195967&partnerID=8YFLogxK

U2 - 10.1089/104303401753204571

DO - 10.1089/104303401753204571

M3 - Article

C2 - 11686941

AN - SCOPUS:0035195967

VL - 12

SP - 2007

EP - 2016

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 16

ER -